Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7340868 | 1.00 | DPP4 (0.77) | DPP4DPP7 | |
| SCHEMBL7335885 | 0.89 | DPP4 (0.62) | DPP4DPP7 | |
| SCHEMBL7335876 | 0.89 | DPP4 (0.62) | DPP4DPP7 | |
| SCHEMBL6595949 | 0.87 | DPP4 (1.00) | DPP4DPP7 | |
| SCHEMBL1436301 | 0.83 | DPP4 (0.69) | DPP4DPP7 | |
| SCHEMBL664934 | 0.83 | DPP4 (0.69) | DPP4DPP7 | |
| Hydrochloric Acid SCHEMBL6699417 | 0.83 | DPP4 (0.60) | DPP4DPP7 | |
| SCHEMBL7346666 | 0.82 | DPP4 (0.65) | DPP4 | |
| SCHEMBL7346656 | 0.82 | DPP4 (0.65) | DPP4 | |
| SCHEMBL4594273 | 0.81 | DPP4 (0.59) | DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | VILLHAUER EDWIN BERNARD (US) | 2002-12-19 | — | — | US | disclosed |
| US-6432969-B1 | NON-INSULIN DEPENDENT DIABETES, OBESITY, ARTHRITIS, AND OSTEOPOROSIS TREATMENT | NOVARTIS AG (CH) | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | DPP4, DPP9, DPP7 | DPP4 1/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.